LCM
ALNY icon

Laurion Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Laurion Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-17,500
Closed -$1.27M – 832
2018
Q4 		$1.27M Buy
+17,500
New +$1.35M 0.02% 503

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Laurion Capital Management's ALNY Position: Q1 2026 in Review

Laurion Capital Management opened a new position in Alnylam Pharmaceuticals (ALNY) in Q1 2026: 4,431 shares worth $1.47M. The stake represents 0.06% of the portfolio and ranks #233 among its holdings. This is a return to the name: Laurion Capital Management previously reported a position in ALNY as recently as Q2 2020.

Laurion Capital Management first reported a position in ALNY in Q4 2016 and has held it in 5 quarters since. The position peaked at $15.5M in Q4 2017. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Laurion Capital Management held 4,431 shares of Alnylam Pharmaceuticals worth $1.47M as of Q1 2026.
  • Alnylam Pharmaceuticals was a new Laurion Capital Management position in Q1 2026.
  • Alnylam Pharmaceuticals made up 0.06% of Laurion Capital Management's portfolio in Q1 2026, its #233 holding.
  • Laurion Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2016 and has held it in 5 quarters since.
  • Laurion Capital Management's Alnylam Pharmaceuticals position peaked at $15.5M in Q4 2017.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Laurion Capital Management's 13F filing for Q1 2026, filed 14 May 2026.